ATP-Binding Cassette Transporter Expression and Methylation Profiles as Potential Biomarkers in Glioma
Gliomas are malignant central nervous system tumors characterized by poor prognosis and therapy failure. Adenosine triphosphate-binding cassette (ABC) transporters mediate multidrug resistance via chemotherapeutic efflux, yet their roles as biomarkers across glioma subtypes remain unclear. We analyzed adult diffuse glioma mRNA expression (n = 693; n = 325) and DNA methylation (n = 159) datasets from the Chinese Glioma Genome Atlas in silico, stratifying samples according to the 2021 World Health Organization molecular criteria. ABC transporter profiles, patient-matched methylation–expression correlations (n = 26 overlapping patients; 78 paired gene–sample observations), and prognostic values were evaluated using non-parametric tests with false discovery rate (FDR) correction, Kaplan–Meier curves, and multivariable Cox proportional-hazards regression analyses. Transporter expression and methylation varied significantly by histology and grade. ABCC1 expression increased with malignancy, predicting worse overall survival in univariable analysis (p < 0.0001). Meanwhile, strongly correlated ABCB1 and ABCG2 expressions (Spearman’s ρ = 0.80 in grade 4 tumors) were higher in lower-grade gliomas. Progressive hypomethylation occurred with increasing grade, with significant differential methylation in ABCB1 (FDR p < 0.0001) and ABCG2 (FDR p < 0.0001). In patient-matched integrative analyses, only ABCC1 exhibited a significant inverse association between methylation and expression (Spearman’s ρ = −0.58, p = 0.0019). Baseline clinical multivariable Cox regression (n = 139) suggested that higher ABCB1 and ABCG2 methylation (HR = 0.11, p = 0.03; HR = 0.12, p = 0.04 per 1.0-unit β increase, corresponding to HR = 0.80 and 0.81 per 0.1-unit β increase) may act as protective factors independent of age and grade (though attenuated upon IDH adjustment), whereas higher grade and ABCG2 expression (n = 542; HR = 1.03, p = 0.001) emerged as independent risk factors. Specific ABC transporter profiles could serve as candidate prognostic biomarkers in glioma, warranting external and translational validation.
Authors
- Vivaldo Moura‐Neto (ORCID: https://orcid.org/0000-0003-0303-1868)
- Carlos Pilotto Heming (ORCID: https://orcid.org/0000-0002-4504-7086)
- Veronica Aran (ORCID: https://orcid.org/0000-0003-2751-0986)
- Yasminn Meireles (ORCID: https://orcid.org/0009-0006-1302-9218)
Institutions
- Universidade Federal do Rio de Janeiro (BR)
- Instituto Estadual do Cérebro Paulo Niemeyer (BR)
Publication Details
- Journal
- International Journal of Molecular Sciences
- Published
- 2026-11-13
- DOI
- https://doi.org/10.3390/ijms272210180
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00